Opportunistic fungal infection occurring frequently in a compromised host is one of the most important problems in modern medicine, because of the difficulty of treatment and the frequency with which such infections progress to a lifethreatening condition. There are many papers reports on the increased susceptibility of tumor-bearing hosts to systemic fungal infections. [2] [3] [4] [5] [6] The protective activity of allogeneic sarcoma 180 tumor-bearing mice against Candida albicans and Aspergillus fumigatus infections has been reported in our previous papers. [7] [8] [9] [10] [11] It has also been reported that there is a significant delay in the lethal response to C. albicans in mice bearing Lewis lung carcinoma. 12) However, the mechanisms of such an effect have yet to be fully elucidated. We reported that the number of peripheral blood polymorphonuclear leukocytes (PMNs) dramatically increased in sarcoma 180 tumor-bearing mice. [7] [8] [9] We also investigated the producibility of the granulocyte-macrophage colony-stimulating factor from the tumor cells. 9, 10) We thought that this phenomenon should be investigated not only in allogeneic tumor-bearing mice but also in syngeneic tumor-bearing mice. In the present study, to demonstrate further the importance of PMNs in the resistance of tumor-bearing mice against C. albicans, we conducted a protection assay against the infection using allogeneic (sarcoma 180) and syngeneic (Meth A fibrosarcoma [Meth A] and MM 46 mammary carcinoma [MM46]) solid tumor-bearing mice over the course of 3 weeks after tumor cell transplantation. Furthermore, we investigated in detail the involvement of PMNs from tumor-bearing mice as the likely mechanism of such protection.
reported. 14) Preparation of the peripheral blood phagocytes (monocytes and PMNs) was conducted in accordance with the previous description.
15 ) The cells were prepared from heparinized blood by dextran sedimentation followed by Lympholyte M differential centrifugation. The obtained cells were distinguished using May-Giemsa staining.
Measurement of Calcium Concentration One, 2, and 3 weeks after tumor cell transplantation, the concentrtation of calcium in the serum from the mice was measured using calcium assay kits (Kanto Chemical Industries Co., Tokyo, Japan).
Candidacidal Activity The candidacidal activity of the phagocytes was determined using a slight modification of a previously described method. 13) Briefly, 1ϫ10 2 -5ϫ10 5 viable C. albicans cells were suspended in 10 ml of HBSS containing 10% normal mouse serum. The suspension was added to a suspension of 1ϫ10 5 PMNs (monocytes, 1ϫ10 4 or macrophages, 1ϫ10 5 ) in 100 ml of the same medium, and the mixture was incubated at 37°C in a 96-well plate. After 3-h incubation, the cells were scraped off with a rubber policeman, and the cell suspension was plated on a Sabouraud agar plate. The number of colonies was counted and expressed as killing (%) using the following formula:
where A and B represent the number of colonies at 0 and 3 h of incubation, respectively.
Chemiluminescence Measurement One and 3 weeks after tumor transplantation, PMNs (1ϫ10 5 cells) collected from the peripheral blood of mice were suspended in 1 ml of HBSS. The luminol-dependent chemiluminescence (CL) response was measured in a Biolumat LB 9500 (Berthold Co., Wildbad, Germany) in accordance with the previous description.
16) The CL response was expressed as counts per minute (CPM). CL is dependent upon several intracellular metabolic events for the adequate generation and utilization of O 2 Ϫ and H 2 O 2 .
17)
Assay of Myeloperoxidase The myeloperoxidase (MPO) activity of the PMNs was measured using the same method as previously described.
12) The activity causing an increase in the absorbancy of 0.001 per minute was expressed as one unit of enzyme activity.
Statistical Analysis Student's t-test and c 2 tests were used to calculate the statistical significance of differences between groups.
RESULTS AND DISCUSSION
Resistance of Tumor-Bearing Mice to C. albicans Infection Numerous papers have been published concerning the significant decline in the function of macrophages, humoral antibody response, and delayed hypersensitivity response in tumor-bearing hosts. [18] [19] [20] However, the function of PMNs from tumor-bearing hosts in microbial infections is not clearly understood. Hosts with acute leukemia have increased susceptibility to systemic Candida infection and also show a reduction in the accumulation and the candidacidal activity of neutrophils. 4, 6) On the other hand, we [7] [8] [9] [10] and others 12) reported that the lethality due to infection with C. albicans was significantly delayed in sarcoma 180 and Lewis lung carcinoma tumor-bearing mice. In the present study, we extensively compared the response against C. albicans infection using 1, 2, or 3-week allogeneic (sarcoma 180) and syngeneic (Meth A and MM 46) solid tumor-bearing mice to clarify the function of PMNs from tumor-bearing mice in further detail. The survival ratios of mice inoculated intravenously with C. albicans cells 1, 2, and 3 weeks after tumor transplantation are shown in Table 1 . Mice inoculated with the fungal cells 1 week after sarcoma 180 tumor transplantation showed nearly the same survival rate as those inoculated with the fungal cells alone. All of these mice died within 10 d after infection. In contrast, mice inoculated with fungal cells 2 or 3 weeks after tumor transplantation had a 100% survival rate 10 d after infection, and the life-span prolongation was similar to that of mice receiving tumor transplantation alone. Syngeneic (Meth A and MM 46) solid tumor (3-week)-bearing mice also showed a significant resistance against C. albicans intravenous infection. /mouse, s.c.) tumor cells were transplanted in ddY, BALB/c or C3H/He mice, respectively. One, 2, and 3 weeks after tumor transplantation, the mice were inoculated with C. albicans cells (2ϫ10 6 /mouse, i.v.). Twenty mice were used for each group. b) pϽ0.001 compared with the non-tumor-bearing mice group, c 2 test.
Number of C. albicans Cells in Kidneys from TumorBearing Mice
To ascertain the degree of enhanced protection against C. albicans infection in tumor-bearing mice, the number of viable yeast cells in the kidney tissue was counted. From the results summarized in Table 2 , it is clear that the number of viable C. albicans cells in the kidneys of mice inoculated with the fungal cells 3 weeks after sarcoma 180 tumor transplantation was significantly less, about 1/6000, than that in normal mice that received the fungal cells alone. 7, 8) However, the number of fungal cells in the kidneys of mice 1 week after tumor implantation was nearly identical to that of mice that received the fungal cells alone. The number of viable fungal cells in Meth A and MM 46 tumor-bearing mice was similar to that in the sarcoma 180 tumor-bearing mice. The fungal cell numbers in the kidneys of tumor-bearing mice correlated with prolonged survival ( Table 1) .
Number of Phagocytes from Tumor-Bearing Mice In previous papers, 6, 7) we reported that the number of peripheral blood PMNs in allogeneic (sarcoma 180) solid tumor-bearing mice increased in proportion to the tumor weight. To determine whether there was a change in the number of monocyte-macrophages and PMNs, the numbers of monocytes and PMNs in the peripheral blood and macrophages and PMNs in the peritoneal cavity of tumor-bearing mice were counted (Table 3 ). The number of peripheral blood monocytes and peritoneal macrophages in the tumor-bearing mice 1, 2, and 3 weeks after tumor challenge was almost the same as in normal mice. However, the number of peripheral blood PMNs in 3-week sarcoma 180 and Meth A tumor-bearing mice had increased about 20-fold and about 10-fold higher, respectively than that found in normal mice. The number of the PMNs in 3-week MM 46 tumor-bearing mice was similar to that in Meth A tumor-bearing mice (data not shown). It is obvious that the tumor-bearing mice had an increase in the number of peripheral blood PMNs with the growth of the tumors.
Susceptibility against C. albicans Infection and Number of Peripheral Blood PMNs in Tumor-Bearing Mice Administered CY It is known that mice receiving a single injection of CY in high doses (greater than 150 mg/kg) 1 to 6 d before inoculation with viable C. albicans show increased susceptibility to the challenge accompanied by a reduction in peripheral blood PMNs. 21) Therefore to investigate the relationship between the protection against C. albicans infection and the number of peripheral blood PMNs, we observed the effect of CY in tumor-bearing mice against C. albicans infection (Table 4 Vol. 27, No. 5 
Development of Hypercalcemia in Tumor-Bearing Mice
Enhanced granulopoiesis is known to occur in animals and humans who bear tumors that produce colony-stimulating factor (CSF). [22] [23] [24] Several papers suggested the presence of a new syndrome of granulocytosis and hypercalcemia associated with CSF-producing tumors. [25] [26] [27] Therefore we measured changes in the serum calcium concentration in tumorbearing mice (Table 6 ). Two and 3 weeks after sarcoma 180 tumor transplantation, the mice showed a significant increase (pϽ0.05 and pϽ0.001, respectively) in the serum calcium concentration (greater than 15 mg/ml) in parallel with granulocytosis ( Table 3 ). The 3-week Meth A tumor-bearing mice also showed increases (pϽ0.001) in the calcium concentration in parallel with granulocytosis. We have already reported that sarcoma 180, Meth A, and MM 46 tumor cells produce granulocyte-macrophage colony-stimulating factors (GM-CSFs). 9, 10) From the present results, it is suggested that the granulopoiesis and hypercalcemia seen in the 3-week tumor (sarcoma 180 and Meth A)-bearing mice were effects of GM-CSF released from the tumor cells, as also described by several authors. [25] [26] [27] Similler results were obtained in the MM 46 tumor-bearing mice (data not shown).
Candidacidal Activity of Peripheral Blood PMNs from Tumor-Bearing Mice Previously, we reported the candidacidal activity of peripheral blood PMNs in sarcoma 180 tumor-bearing mice. 7, 8) The experiments were conducted to confirm the candidacidal activity by changing the ratio of the fungal cells and PMNs. Table 7 shows that a fixed number of PMNs of 1ϫ10 5 from 3-week sarcoma 180 tumor-bearing mice can exhibit a stronger killing effect than that from the non-tumor-bearing mice using more than 2ϫ10 5 fungal cells (pϽ0.01 and pϽ0.001, respectively). However, the PMNs from 1-week sarcoma 180 tumor-bearing mice did not show any enhancement of the killing effect. These results clearly show that PMNs in mid-stage tumor-bearing mice can kill Candida cells more potently. Similar activity was also found in PMNs from the Meth A and MM 46 tumor-bearing mice W, week. a) Sarcoma 180 (1ϫ10 6 /mouse, s.c.) and Meth A (1ϫ10 6 /mous, s.c.) tumor cells were transplanted in ddY or BALB/c mice, respectively. One, 2, and 3 weeks after tumor transplantation, the serum calcium concentration in noninfected tumor-bearing mice was measured using calcium assay kits. Data represent the meanϮS.D. of 4 mice. b) pϽ0.05 compared with the non-tumor-bearing mice group, Student's t-test. c) pϽ0.01 compared with the non-tumor-bearing mice group, Student's t-test. (data not shown). On the other hand, both peripheral blood monocytes and peritoneal macrophages from 3-week sarcoma 180 tumor-bearing mice did not exhibit any enhancement of killing activity compared with that in non-tumorbearing mice (data not shown). These results indicate that PMNs are the most important phagocytes involved in the killing of Candida cells in the mid-stage tumor-bearing mice.
Active Oxygen Generation and Myeloperoxidase Activity of Peripheral Blood PMNs from Tumor-Bearing Mice It is well known that the most important Candida killing factors are the active oxygens, especially hydrogen peroxide, and MPO of PMN. [28] [29] [30] Therefore the CL response and MPO activity of peripheral blood PMNs collected from mice 1 and 3 weeks after tumor transplantation were compared with those of PMNs from normal mice, as shown in Table 8 . The CL response of a fixed number of PMNs (1ϫ10 5 cells) from normal mice, 1-week tumor-bearing mice, and 3-week tumor-bearing mice was 0.9ϫ10 4 , 1.8ϫ10 4 , and 3.6ϫ10 4 CPM, respectively. It is clear that the increase in the active oxygen-generating activity per total cells was proportional to the tumor weight and the PMN number, and a markedly increased level of activity was maintained even 3 or more weeks after tumor transplantation. 7, 8) The MPO activity of a fixed number of PMNs (1ϫ10 6 cells) from normal mice, 1-week tumor-bearing mice, and 3-week tumor-bearing mice was 30, 22, and 122 U, respectively. This activity per total cells was also maintained at a markedly increased level from the mid-to the final stage in tumor-bearing mice. The increase in these killing factors was also found in Meth A and MM 46 tumor-bearing mice (data not shown). It is reasonable to assert that the remarkable increase in these killing factors reflects stronger candidacidal activity (Table 7) .
From these results, we suggest that PMNs play an important role in the protection of tumor-bearing mice against C. albicans infection; the greater the decreases in PMNs, the weaker the protection against C. albicans infection. Based on the results of this study, we conclude that the protective effect against C. albicans infection is observed in 2-3-week tumor-bearing mice and that the increase in the number and killing activity of PMNs is important in the mechanism of action. It appears that increases in both the quantitative and qualitative activities of PMNs are necessary to protect against infection in tumor-bearing mice. Therefore we emphasize that careful surveillance of the immunologic and physiologic status during medical treatment to prevent deepseated mycosis in cancer patients is needed. As we showed in this investigation, the importance of PMNs in the protection of not only allogeneic (sarcoma 180) tumor-bearing mice but also syngeneic (Meth A and MM 46) tumor-bearing mice against C. albicans infection, we must direct the next challenge to developing human cancer-like tumor-bearing animals and/or carcinogen-induced tumor-bearing animals as human cancer models. Because of their importance in current medical therapy, we will continue our more detailed studies of tumor-bearing hosts and infections. 
